Fig. 1From: Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III triala-b, Kaplan-Meier curves by arm and ECOG status for overall survival (a) and progression-free survival (b). c, Cumulative incidence function of cancer death from competing risk survival analysis by arm and ECOG status. P values were from log-rank tests for a and b, and from Fine and Gray’s method for c. PC = paclitaxel/carboplatin; EP = etoposide/cisplatin; ECOG = Eastern Cooperative Oncology Group performance scoreBack to article page